

VALEANT PHARMACEUTICALS INTERNATIONAL

Form 424B3

February 25, 2005

PROSPECTUS SUPPLEMENT NO. 6
(To Prospectus dated August 6, 2004)**Valeant Pharmaceuticals International****\$240,000,000 3.0% Convertible Subordinated Notes due 2010****\$240,000,000 4.0% Convertible Subordinated Notes due 2013
and the Common Stock Issuable upon Conversion of the Notes**

This prospectus supplement relates to the resale by various selling securityholders of \$240,000,000 aggregate principal amount of our 3.0% convertible subordinated notes due 2010, \$240,000,000 aggregate principal amount of our 4.0% convertible subordinated notes due 2013 and shares of our common stock into which the notes are convertible. This prospectus supplement may only be delivered or used in connection with our prospectus dated August 6, 2004. Our common stock is quoted on the New York Stock Exchange under the symbol VRX.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

Prospectus Supplement No. 6 dated February 25, 2005.

The information appearing in the following table supplements or supersedes (where the name of the selling securityholder appears in our prospectus or any supplement thereto) in part the information in the table under the heading "Selling Securityholders" in our prospectus (as amended by any previous prospectus supplement) and was provided by or on behalf of the selling securityholders.

Name of Selling Securityholder(1)	Principal Amount of Notes Beneficially Owned Prior to This Offering	Principal Amount of Notes Offered by This Prospectus	Number of Shares of Common Stock That May Be Sold(2)	Percentage of Common Stock Outstanding
4.0% convertible subordinated notes due 2013 (CUSIP No. 91911XAC8)				
McMahan Securities Co. L.P.	\$ 100,000	\$ 100,000	3,136	*
All other holders of 4.0% convertible subordinated notes due 2013 or shares of common stock issued on conversion of such notes and future transferees, pledgees, donees, and successors thereof(3)	\$36,618,000	\$36,618,000	1,158,359	1.36%

* Less than 1%.

- (1) Information concerning the selling securityholders may change from time to time. Any such changed information will be set forth in amendments or supplements to our prospectus dated August 6, 2004, if and when required.
- (2) Unless otherwise indicated, includes all shares of common stock issuable upon conversion of the notes and assumes a conversion rate of 31.6336 shares for each \$1,000 principal amount of notes and a cash payment in lieu of any fractional share. However, this conversion rate will be subject to adjustment as described under "Description of the Notes - Conversion Rate Adjustments." As a result, the number of shares of common stock offered hereby may increase or decrease in the future. Also assumes that the notes are convertible immediately. As described above under "Description of the Notes - Conversion of Notes," the notes are convertible only in specified circumstances.

Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 424B3

- (3) Information concerning other selling securityholders will be set forth in amendments or supplements to our prospectus dated August 6, 2004, if required.

The following information supplements in part the information under the heading "Plan of Distribution" in our prospectus and was provided by or on behalf of the selling securityholders:

The following selling securityholder is a registered broker-dealer that obtained its notes other than as compensation for services: McMahan Securities Co. L.P. As a result, it is deemed to be an "underwriter" within the meaning of Section 2(11) of the Securities Act.